A System Dynamics-Based Evaluation of the Mandatory Offer of HIV Testing in New York State Health Economics Resource Center Cyber-Seminar March 14, 2013.

Slides:



Advertisements
Similar presentations
Diagnosis and Management of Acute HIV Infection HIV Clinical Guidelines from the New York State Department of Health AIDS Institute January 2010 HIV CLINICAL.
Advertisements

Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County Shoshanna Nakelsky, MPH Division of HIV and.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Karen McCraw Chief Program Officer Family First Health.
HIV Testing in Health-Care Settings
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Late HIV Diagnoses, Georgia,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Illustrating the HIV Care Continuum in U.S. Cities
Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
HIV Care Continuum for the United States and Puerto Rico National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.
1 Risks and Benefits of Home-Use HIV Test Kits Richard Forshee, Ph.D. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office.
HIV Testing in Health- Care Settings Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings U.S. Centers.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
Illustrating the HIV Care Continuum in U.S. Cities Chicago, IL.
Illustrating the HIV Care Continuum in U.S. Cities New Orleans, LA.
Illustrating the HIV Care Continuum in U.S. Cities Atlanta, GA.
Illustrating the HIV Care Continuum in U.S. Cities Philadelphia, PA.
© 2005, Johns Hopkins University. All rights reserved. Department of Health, Behavior & Society David Holtgrave, PhD, Professor & Chair.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Meredith Carr, JD J. Stan Lehman, MPH David W. Purcell, JD, PhD Division of HIV/AIDS Prevention Centers for Disease Control and Prevention July 25, 2012.
Community Feedback and Involvement in [Health Department’s] Proposed Data to Care Program [Name of Provider Session Date of Provider Session]
Health promotion and health education programs. Assumptions of Health Promotion Relationship between Health education& Promotion Definition of Program.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
Michael J. Mugavero, M.D., MHSc, Jessica A. Davila, Ph.D., Christa R. Nevin, MSPH, and Thomas P. Giordano, M.D., M.P.H. Volume 24, Number 10, 2010 AIDS.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
eHARS to CAREWare Pilot Project Update and Training
Division of HIV/AIDS Prevention CDC-RFA-PS
HIV Care Continuum, Georgia, United States, 2011 Presented to American Public Health Association, Annual Meeting Presented by Deepali Rane, MBBS, MPH,
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.
HIV Care Continuum Persons Living With HIV, Georgia, 2012.
Kow-Tong Chen, M.D., Ph.D., Hsiao-Ling Chang, Ph.D., Chu-Tzu Chen, M.P.H., and Ying-An Chen, M.P.H. Volume 23, Number 3, 2009 AIDS PATIENT CARE and STDs.
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
Linking Data with Action Part 1: Seven Steps of Using Information for Decision Making.
The HIV Care Continuum: A Tool for Driving Systematic Change to Support Better Engagement in Care Jeffrey S. Crowley Distinguished Scholar/ Program Director.
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
ANALYZING THE INTEGRATION OF HIV TESTING INTO THE FLOW OF FAMILY PLANNING CLINICS JANUARY 29, 2009 Rapid Testing & Clinic Flow 1.
From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
State Office of AIDS Update
CHS Community Health Survey
Illustrating the HIV Care Continuum in U.S. Cities
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Illustrating the HIV Care Continuum in U.S. Cities
NYSDOH AIDS Institute Quality of Care Program eHIVQUAL
Illustrating the HIV Care Continuum in U.S. Cities
HIV Diagnosis and the Cascade of Care in Ontario
Illustrating the HIV Care Continuum in U.S. Cities
Retention: What It Means for You
Poster WP41; Contact: David A. Katz,
Needs Assessment Slides for Module 4
Estimating the State-Specific Impact of the HRSA Ryan White HIV/AIDS Program December 13, 2018 Pamela Klein, MSPH, PhD Health Scientist, Division of Policy.
Steven M. Goodreau1,2,3*, Emily D. Pollock1,2, Li Yan Wang4, Richard L. Dunville4, Lisa C. Barrios4, Maria V. Aslam5, Meredith A. Barranco6, Elizabeth.
TRACE INITIATIVE: Data Use
D. T. Hamilton, MPH PhD, S. M. Goodreau, PhD, S. M. Jenness, PhD, P. S
TRACE INITIATIVE: Overview
Illustrative Cluster Detection and Response Strategy
Stakeholder engagement and research utilization: Insights from Namibia
Presentation transcript:

A System Dynamics-Based Evaluation of the Mandatory Offer of HIV Testing in New York State Health Economics Resource Center Cyber-Seminar March 14, Erika Martin, PhD MPH Rockefeller College of Public Affairs & Policy, University at Albany Nelson A. Rockefeller Institute of Government State University of New York

Acknowledgments SUNY-Albany: – Roderick MacDonald, PhD New York State Department of Health AIDS Institute: – Daniel O’Connell, MA MLS – Lou Smith, MD MPH – Daniel Gordon, PhD – James Tesoriero, PhD – Franklin Laufer, PhD – John Leung, MS Centers for Disease Control and Prevention HIV prevention projects cooperative agreement 2

Roadmap Motivation for system dynamics policy evaluation Research methods – System dynamics modeling approach – HIVSIM model of New York HIV testing and treatment system Results: baseline projections, in absence of the law Results: potential effects of the law Key model insights 3

New York State HIV testing law Effective September 1, 2010 Aims to increase HIV testing and subsequent entry into care and treatment Key features: – HIV testing required in routine medical care (ages 13-64) – Simplified informed consent and pre-test counseling – Providers/facilities offering HIV tests must arrange follow-up care appointments Statutory requirement for Commissioner of Health to evaluate the number of HIV tests and number who access care and treatment; due September 1,

Rationale for system dynamics modeling study Quantitative data (surveys, administrative data, surveillance system) may not address complexities in the system of HIV testing and care Qualitative research can examine nuances, but cannot generate quantitative predictions Empirical data from other evaluation studies limited to short time horizon and measurable outcomes Law implemented in context of multiple concurrent policies that may affect outcomes 5

Features of system dynamics models Analyze problems in complex social, managerial, economic, or ecological systems, at the population level Work closely with stakeholders and experts to develop system structure and incorporate data Holistic view of the interaction of organizations and processes in system producing system-wide results Feedback loops to model dynamic system processes Nonlinearities in relationships among variables Dynamic implications of policies, why and how outcome will change, potential unintended consequences, areas where implementation may not lead to intended outcomes 6

Methods overview Computer simulation model of HIV testing and care in New York State (HIVSIM) Data sources used for HIVSIM parameters and calibration – HIV surveillance system (NYSDOH) – Medicaid claims (NYSDOH) – Incidence estimates (NYSDOH, using CDC methodology) – Expert opinion – Published literature Counterfactual analyses of short- and long-term outcomes under alternate implementation scenarios Results presented as graphs over time; % changes over time and across scenarios (“differences in differences”) 7

HIVSIM stock and flow diagram 8

10

HIVSIM stock and flow diagram 11

Stock and flow diagram: zoomed in 12

Key features of HIVSIM 13 Disease progression (acute to late stage)

Key features of HIVSIM 14 Slower disease progression for individuals in treatment

Key features of HIVSIM 15 Diagnosis and engagement in care

Dynamics of different transmission rates Unaware individuals transmit 3.5 times more infections than diagnosed individuals (risk behaviors, viral load) 75% of New Yorkers engaged in care have a transmission rate of zero (complete viral suppression) 25% of new infections are attributable to acutely infected individuals Assumption that individuals in stages 1-3 (early, mid, late) have identical transmission rates 16

Different transmission rates in HIVSIM 17 Higher transmission rates for individuals who are unaware and in acute stage disease

Different transmission rates in HIVSIM 18 Very low transmission rates for individuals who are engaged in care and have achieved viral suppression

HIVSIM stock and flow diagram: HIV testing structure 19

Mapping between the diagrams 20 Population eligible for testing Population that previously tested positive

Mapping between the diagrams 21 Population that previously tested positive Population eligible for testing (uninfected and unaware)

HIVSIM stock and flow diagram: HIV testing structure 22 “Not Recently” and “Recently” tested refers to offers in routine care (incremental testing)

23 Time delay between test offers in routine care (specified by modelers) HIVSIM stock and flow diagram: HIV testing structure

24 Anyone can be diagnosed as part of background testing (even if ineligible for another test in routine care) HIVSIM stock and flow diagram: HIV testing structure

25 Individuals eligible for a test in routine care may also be diagnosed through incremental testing HIVSIM stock and flow diagram: HIV testing structure

26 Uninfected individuals may subsequently become infected and diagnosed through background or incremental testing HIVSIM stock and flow diagram: HIV testing structure

Recap of dynamic model features HIVSIM aggregates individual trajectories (disease progression, engagement in care) at the population level Dynamic feedback: – Existing cases generate new infections – Infectiousness and health outcomes (survival, mortality) change depending on disease stage and level of engagement in care Nonlinear feedback: – Continued testing of the whole population will result in a lower yield 27

Policy scenarios No law Level of implementation (perfect, high, and low) Frequency of repeat testing in routine care (annual, five-year, and one-time) Perfect viral suppression among individuals in care Range of implementation times (18 months to five years) All scenarios represent implementation of incremental testing in routine care settings, and assume New Yorkers also continue to be diagnosed as part of background testing 28

Outcome variables Increase in HIV tests* New infections Newly diagnosed HIV cases; newly diagnosed AIDS cases; fraction of newly diagnosed cases with concurrent AIDS Diagnosed HIV cases newly linked to care*; diagnosed HIV cases ever linked to care; diagnosed HIV cases currently engaged in care People living with diagnosed HIV infection; people living with HIV (diagnosed and undiagnosed) Fraction of HIV cases who are undiagnosed 29 * Law requires that the NYSDOH evaluate impact of statute with respect to “number of persons tested for HIV infection” and “number of persons who access care and treatment”

Baseline projections, in absence of law Continuing decline in annual new infections, annual new diagnoses, and fraction of undiagnosed cases Slight increase in people living with diagnosed HIV infection and diagnosed HIV cases currently in care Explanations: current HIV prevention efforts, system delays, survival and transmission benefits of antiretroviral therapy 30

Potential impact of law, if implemented as designed Reductions in annual new infections and fraction of undiagnosed cases Initial surge then decline in newly diagnosed HIV cases per year Steady decline in newly diagnosed AIDS cases per year Explanations: rapid identification of unaware individuals, individuals diagnosed earlier before progressing to late stage disease 31

If implemented as designed, the HIV testing law will lead to fewer new infections. 32 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation No law Perfect implementation

If implemented as designed, the HIV testing law will lead to fewer newly diagnosed AIDS cases. 33 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation No law Perfect implementation

If implemented as designed, the HIV testing law will reduce the fraction of undiagnosed cases. 34 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation No law Perfect implementation

If implemented as designed, the HIV testing law will lead to an initial surge then decline in newly diagnosed HIV cases. 35 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation No law Perfect implementation

Potential impact of law, if implemented as designed No surge in individuals newly linked to care annually (relative increase, not absolute increase) Minimal changes in people living with diagnosed HIV infection and number of cases in care Number of annual new infections and fraction of undiagnosed cases do not approach zero Explanations: declining trend in individuals newly linked to care, people stay in care for long time due to system delays, ongoing transmissions from individuals unaware and diagnosed cases not virally suppressed 36

Even under perfect implementation, there will not be a large surge in diagnosed cases newly linked to care. 37 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation No law Perfect implementation

Even under perfect implementation, there will be minimal differences in people living with diagnosed HIV infection. 38 Results for scenarios of annual repeat testing in routine care (in addition to continued targeted risk-based testing), and three levels of implementation

Comparison of level of implementation vs. testing frequency Frequency of testing in routine care (annual, five-year, and one-time) – Overall minimal differences in outcomes – Largest difference is number of tests performed per year Level of implementation (perfect, high, low) – Increasing level of implementation improves new infections, newly diagnosed cases, fraction of newly diagnosed cases with concurrent AIDS, and fraction of undiagnosed cases 39

Sensitivity analysis on time to implementation No substantial changes if implementation time is varied Surges in new diagnoses and individuals newly linked to care appear larger, but outcomes are similar by the end of the period Explanations: unaware individuals are identified more quickly; because the unaware population relatively small, diagnosing them a few years earlier does not have dramatic changes on new infections 40

Perfect viral suppression Perfect viral suppression among individuals in care yields similar improvements in annual new infections, compared to perfect implementation Largest impact on new infections is from perfect viral suppression among individuals in care and perfect implementation of the testing law 41

Perfect viral suppression among individuals in care yields similar reductions to new infections. 42 Perfect implementation VL suppression

Limitations All models are imperfect representations of reality No empirical data for some parameters True “level of implementation” unknown 43

Key model insights Continue to invest resources in programs that provide HIV medical care, improve retention in care, encourage reductions in risky behaviors Temporary increases in new HIV diagnoses under the law will be offset by an anticipated decline in new infections and new diagnoses under baseline projections Continue to use broad policy approach with wide range of HIV prevention interventions, in addition to HIV testing law 44

Key model insights One-time testing in routine care (in addition to continued targeted testing) is most efficient use of resources Useful indicators of the law’s success are newly diagnosed HIV cases and newly diagnosed AIDS cases per year 45

Thank you! Feel free to contact me at: Erika Martin phone: